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In hyperglycemia, glucagon-like peptide-1 (GLP-1) lowers brain glucose concentration
together with increased net blood-brain clearance and brain metabolism, but it is not
known whether this effect depends on the prevailing plasma glucose (PG) concentration.
In hypoglycemia, glucose depletion potentially impairs brain function. Here, we test the
hypothesis that GLP-1 exacerbates the effect of hypoglycemia. To test the hypothesis,
we determined glucose transport and consumption rates in seven healthy men in
a randomized, double-blinded placebo-controlled cross-over experimental design. The
acute effect of GLP-1 on glucose transfer in the brain was measured by positron
emission tomography (PET) during a hypoglycemic clamp (3mM plasma glucose) with
18F-fluoro-2-deoxy-glucose (FDG) as tracer of glucose. In addition, we jointly analyzed
cerebrometabolic effects of GLP-1 from the present hypoglycemia study and our previous
hyperglycemia study to estimate the Michaelis-Menten constants of glucose transport and
metabolism. The GLP-1 treatment lowered the vascular volume of brain tissue. Loading
data from hypo- to hyperglycemia into the Michaelis-Menten equation, we found increased
maximum phosphorylation velocity (Vmax) in the gray matter regions of cerebral cortex,
thalamus, and cerebellum, as well as increased blood-brain glucose transport capacity
(Tmax) in gray matter, white matter, cortex, thalamus, and cerebellum. In hypoglycemia,
GLP-1 had no effects on net glucose metabolism, brain glucose concentration, or blood-
brain glucose transport. Neither hexokinase nor transporter affinities varied significantly
with treatment in any region. We conclude that GLP-1 changes blood-brain glucose
transfer and brain glucose metabolic rates in a PG concentration-dependent manner. One
consequence is that hypoglycemia eliminates these effects of GLP-1 on brain glucose
homeostasis.
Keywords: glucagon-like peptide -1, hypoglycemia, hyperglycemia, blood-brain barrier, cerebral metabolic rate for
glucose, Michaelis-Menten, cerebral glucose transport
INTRODUCTION
Brain energy metabolism almost exclusively depends on a steady
supply of circulating glucose. The adequacy of the glucose deliv-
ery in turn depends on the glucose concentration in plasma.
Therefore, hypoglycemia can induce brain dysfunction and hypo-
glycemic symptoms (Maran et al., 1995). Glucagon-like peptide-1
(GLP-1) is produced in the brain by neurons in the nucleus of
the solitary tract where it acts as a neuropeptide, as well as in the
gut. GLP-1 has beneficial effects on both peripheral (Holst, 2007)
and cerebral glucose homeostasis (Lerche et al., 2008; Gejl et al.,
2012a). Central GLP-1 signaling is linked to the control of blood
glucose concentrations (D’Alessio et al., 2005), and studies reveal
extrapancreatic effects of GLP-1 (Vella and Rizza, 2004; Bak et al.,
2011; Gejl et al., 2012b).
Glucose is supplied to the brain by the stereospecific and non-
energy-demanding mechanism of facilitated diffusion, mediated
by the GLUT1 transporter at the blood-brain barrier (BBB)
(Gjedde, 1983). The equation of Michaelis and Menten (1913)
describes the relationship between glucose transport across the
BBB and the glucose concentration in plasma (Crone, 1965)
and it is in turn consistent with an inverse relation between
the glucose extraction and the glucose concentration, such that
the glucose extraction fraction falls in hyperglycemia (Gjedde,
1981; Hasselbalch et al., 2001) and rises in hypoglycemia
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(Blomqvist et al., 1991). As insulin has no direct effect on blood-
brain glucose transfer, it remains uncertain how glucose transport
across the BBB is regulated by factors other than the concen-
tration of glucose (Hasselbalch et al., 1999) and the transport
capacity of the GLUT1 transporter.
Previously, in hyperglycemia, we showed that GLP-1 lowers
the glucose concentration in brain tissue (Ctissue) in association
with increased net clearance of glucose across the BBB (Gejl
et al., 2012a). With an unaltered transporter transport capac-
ity (Tmax) of the GLUT1 transporter in the BBB, we reasoned
that the most likely explanation is an increase of the maximum
velocity of phosphorylation (Vmax), but the findings were not
conclusive, as we observed the cerebral metabolic rate for glu-
cose (CMRglc) to be increased in several regions but not in the
brain as a whole. This hypothetical increase of Vmax, leading to
less increase of Ctissue in response to the elevated plasma glucose,
could contribute to GLP-1’s neuroprotective effect at normal and
higher glucose levels. Net glucose transfer is mediated by GLUT1
transporters in glial membranes as well as GLUT3 transporters in
neuronal membranes, in addition to the GLUT1 transporters in
the two membranes of the microvascular endothelium (Gjedde
and Christensen, 1984; Simpson et al., 2007).
Glucose delivery falls when plasma glucose (PG) concentra-
tions decline, but it is uncertain how GLP-1 affects the transport
through the multiple membranes of the BBB and the brain cells
in hypoglycemia, which limits the blood-brain glucose exchange.
The main effect of hypoglycemia on blood-brain glucose deliv-
ery is a reduction of the unidirectional and net glucose fluxes
across the BBB, as described by the Michaelis-Menten formal-
ism. A hypothetical effect of GLP-1 directly on the magnitude
of Vmax would be expected to increase the phosphorylation rate
even at hypoglycemia and the accompanying low tissue glucose
level, because of the very high affinity (i.e., low KM) of hexoki-
nase. A further effect of GLP-1 on blood-brain glucose transfer
and glucose metabolism in the brain would accentuate the effects
of hypoglycemia, with increasingly adverse results due to the low
glucose.
Hypoglycemia is associated with reduced brain glucose con-
tent whether subjects remain aware or unaware of the change.
To test the prediction that GLP-1 exacerbates the effect of hypo-
glycemia, we measured the transport and metabolism of the
glucose tracer 18F-fluoro-2-deoxy-glucose (FDG) by positron
emission tomography (PET) in the hypoglycemic state with and
without the presence of GLP-1. We then pooled the findings with
data obtained in hyperglycemia with and without GLP-1 (Gejl
et al., 2012a), to reveal changes of the maximum phosphorylation
and transport capacities (Vmax, Tmax) and the transport affinity
of hexokinase (KM) and GLUT1 (Kt).
MATERIALS AND METHODS
Seven non-smoking, healthy, Caucasian males with a mean age
of 22.9 ± (SD) 1.9 years and a mean body mass index of 22.7 ±
2.7 kg m−2 participated in the study. They had a normal physical
examination, no history of diabetes or cardiovascular disease, and
received no medication.
The study was conducted in accordance with the Declaration
of Helsinki and the protocol was approved by the official
Regional Science Ethics Committee of County Aarhus. All
participants received both oral and written information and
signed an approved informed consent form before entering the
study.
The study proceeded as a randomized, double-blinded,
placebo-controlled, crossover study. Each subject was studied
twice in random order with GLP-1 and placebo infusion. PET
sessions were separated by an interval of 2–6 weeks. Both ses-
sions commenced at 9.00 h after an overnight fast. The subjects
were instructed not to exercise 24 h prior to the sessions. Subjects
were placed in bed and two catheters were inserted for infusion
of clamp hormones and for the infusion of GLP-1 or placebo. A
third catheter was placed in an arterialized (heated) dorsal hand
vein for blood sampling. An arterial catheter was placed in the
radial artery of the right arm in order to draw blood samples for
measuring input radioactivity during PET.
A stepwise hypoglycemic pancreatic-pituitary clamp was per-
formed according to principles previously described (Degn et al.,
2004; Lerche et al., 2008; Gejl et al., 2012a). In brief somatostatin
(Ferring GmbH, D-24109 Kiel) was infused at a rate of 50μg/min
to suppress the endogenous insulin, glucagon, growth hormone
(GH) and GLP-1 production. Human glucagon (Glucagen, Novo
Nordisk A/S, Copenhagen, Denmark) 0.6 ng/kg/min and GH
(Genotropin Miniquik 0.2 mg, Pfizer ApS, Ballerup, Denmark)
2 ng/kg/min were infused with the aim of maintaining near
basal levels (0–360min). Insulin (Actrapid, Novo Nordisk A/S,
Copenhagen, Denmark) was infused at a rate of 0.8 mU/kg/min.
Glucose (200 g/l) was infused at a variable rate to initially clamp
PG at 4.5mM (0–150min). From 150 to 180min, PG was low-
ered to 4.0mM and maintained at this level until 210min.
From 210min to 240min PG was lowered to 3.5mM and main-
tained at this level until 270min. From 270min to 300min
PG was lowered to a nadir of 3.0mM and maintained at this
level during PET (300–360min). GLP-1 or placebo infusion
was initiated at time 60min and maintained during the entire
session.
The subjects received either intravenous synthetic GLP-1
(7–36 amide) or placebo at a rate of 1.2 pmol/kg/min
(60–360min) (Toft-Nielsen et al., 1999). Recombinant human
GLP-1 (7–36 amide) from BioNebraska Inc., Lincoln, NE (USA)
was tested and found positive for sterility and negative for bac-
terial endotoxins before use. It was dissolved in a sterile buffer
containing 600mg of acetic acid, 50.7 g of mannitol and sterile
water added up to 1000 g and had a pH of 4.5. The concentra-
tion of GLP-1 (7–36 amide) was 1mg/ml and it was stored frozen
in vials of 0.25ml. The test solution consisted of 0.25ml GLP-1,
20ml of human albumin “ZLB” 5% and sodium chloride (9 g/l)
to yield 100ml of solution. The placebo solution consisted of the
above mentioned buffer solution containing human albumin and
saline. One subject experienced transient nausea and vomiting
during GLP-1 infusion with onset at 20min of infusion, last-
ing approximately 1½h. Another subject experienced headache
during placebo infusion after 2 h of infusion, lasting 1 h.
PG was measured in duplicate every 10min until it reached
3.0mM and then every fifth minute. Blood for measuring insulin,
c-peptide, glucagon, GLP-1 (total and intact), GH, free fatty acids
(FFA), cortisol and ghrelin was drawn every 30min. Blood for
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measuring epinephrine and norepinephrine was drawn at 0, 150,
and 240min and every 30min during the PET scan. Arterial
blood for measuring input radioactivity was drawn at predeter-
mined intervals during PET (12 × 5 s, 8 × 30 s, and 8 × 300 s).
HYPERGLYCEMIA STUDY
We incorporated the observations of cerebrometabolic effects of
GLP-1 in hyperglycemia, presented by Gejl et al. (2012a).
ASSAYS
Assays were described previously (Lerche et al., 2008). Arterial
input samples were analyzed on a Packard radioactivity analyzer
immediately after each PET session.
MRI
A high resolution T1-weighted MR was acquired for each sub-
ject with a 3.0 T Signa Excite GE Magnet using a 3DIR-fSPGR
sequence.
PET
FDG was used as a tracer for brain glucose uptake and was
produced in-house according to the Drug Master File, Danish
national marketing authorization number 2165. We used the
whole-body PET EXACT HR47 (Siemens Medical, Knoxville,
USA) with a 15 cm field-of-view and an acquisition capacity of 47
transaxial planes with a spatial resolution of 4–5mm at the cen-
ter of the field of view. All PET data were acquired in 3D mode. A
15-min transmission scanwas performed to correct photon atten-
uation. Five hours after clamp start and 4 h after the GLP-1 or
placebo infusion was started, a bolus of 200MBq of FDG in 10ml
saline was injected intravenously over 10 s. Dynamic acquisition
commenced at the beginning of tracer injection and continued
for 45min to acquire 23 frames (6 × 30 s, 7 × 1min, 5 × 2min,
and 5 × 5min).
IMAGE ANALYSIS
PET and MR-images were co-registered and entered in Talairach
space.
Regional tissue time-activity-curves for FDG uptake were
extracted for total cerebral gray matter, cerebral cortex, thalamus,
striatum, cerebellar cortex, brainstem, and white matter.
KINETIC ANALYSIS
Using a 3-compartment model, we obtained values of K∗1 (unidi-
rectional clearance where symbols marked with asterisk indicate
FDG), k∗2 (efflux rate constant), k∗3 (phosphorylation rate con-
stant) and Vp (volume of tissue occupied by intravascular blood)
for FDG in each region-of-interest. The rate of dephosphory-
lation and the absolute quantity of FDG were both considered
negligible during the scanning period. In the use of FDG to
trace glucose metabolism, the “lumped constant” is a necessary
isotope correction factor. In the model, the lumped constant is
the ratio between the net uptakes of FDG and glucose which
depends on the transport across the BBB and the phosphory-
lation of both. This relationship causes the lumped constant to
increase in hypoglycemia compared to normo- or hyperglycemia.
In the competition between native glucose and FDG in the brain,
both transport across the BBB (K∗1 , k∗2) and phosphorylation
by hexokinase (k∗3) obey the Michaelis-Menten equation, which
yields fixed ratios of transport clearances (τ = K∗1 /K1) and phos-
phorylation rates (ϕ = k∗3/k3) for the tracer (marked by asterisk)
and native glucose (no asterisk) (Kuwabara et al., 1990). By sub-
stituting transfer constants of FDG for those of glucose, using the
constants τ and ϕ, we determined the lumped constant directly
for each subject in each region-of-interest as described previously
(Kuwabara et al., 1990), using the values of τ = 1.48 andϕ = 0.39
(Hasselbalch et al., 1998).
The net clearance of FDG is then (Gjedde, 1982)
K∗ = K∗1 k∗3/
(
k∗2 + k∗3
)
and the unidirectional glucose flux from blood into brain is
calculated from the unidirectional FDG clearance as,
Jglc = K∗1 Ca/τ,
where Jglc is the unidirectional flux of glucose from blood to brain,
Ca is the arterial steady state PG concentration (300–360min),
and symbols marked with asterisk indicate FDG.
The unidirectional clearance of glucose is by definition
K1glc = K1/τ
With these constants the lumped constant has been shown to
equal,
LC = ϕ + (τ − ϕ) (k∗3/
(
k∗2 + k∗3
))
and the net clearance of glucose by definition is (Gjedde, 1982)
K = K∗/LC
such that the net cerebral metabolic rate for glucose is calculated
from the net FDG clearance as,
CMRglc = K∗ Ca/LC,
and the cerebral tissue glucose concentration Ctissue is
Ctissue = τ
(
Jglc − CMRglc
)
/k∗2 .
From the equation of Michaelis and Menten (1913), the relation-
ship between cerebral metabolic rate and Ctissue is defined as,
CMRglc = Vmax × Ctissue/ (KM + Ctissue)
where Vmax is the maximal phosphorylation velocity and KM is
the half-saturation-concentration of glucose.
The relationship between glucose transport across the BBB and
glucose concentration in plasma likewise is defined as:
Unidirectional flux
(
Jglc
) = Tmax × Ca/(Kt + Ca)
where Tmax is the maximal transport capacity and Kt is the half-
saturation-concentration of plasma glucose.
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CALCULATIONS AND STATISTICS
The PET-data were analysed using a linear mixed effects model
with subject and all interactions involving subject, including the
interaction between subject and area and the interaction between
subject and treatment, as random effects. Treatment (GLP-1
vs. placebo), region, and the interaction between the two were
included in the analysis as fixed effects. To compare the two treat-
ment groups regarding circulating hormones and metabolites a
similar statistical model was used with time instead of region.
In the analysis of the hypoglycemia study vs. the hyperglycemia
study, we modified the linear mixed effects model to include an
extra systematic factor (PG: hypoglycemia/hyperglycemia) along
with all interactions between PG, treatment, and region as fixed
effects. Significant differences were demonstrated with a sig-
nificance level of P < 0.05. The statistical software used was
GraphPad Prism (GraphPad Software, San Diego, CA, USA) and
Stata (StataCorp LP, College Station, Texas, USA) Data are pre-
sented as mean ± SD. The study was planned as preliminary
exploration and thus the number of subjects that entered the
study did not derive from a power calculation.
All measurements corresponding to a single patient were
excluded from the analysis due to values of Ctissue that were
two orders of magnitude larger than for the other patients.
Michaelis-Menten curves were fitted to the pooled data from
the hypo- and hyperglycemia studies in each region using non-
linear regression and taking into account that all patients were
given both GLP-1 and placebo by including a random subject
effect for each coefficient in the Michaelis-Menten model. The
rate constants (KM and Kt) did not vary significantly with treat-
ment in any region (all p-values above 0.17) and therefore a
model with only one rate constant for each region was used
to increase numerical stability. The data were analysed using
nlme in R 2.15.0 [R Development Core Team (2012). R: A lan-
guage and environment for statistical computing. R Foundation
for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0,
URL http://www.R-project.org/]. We used the in-house program
iFit (www.liver.dk/ifit.html) for kinetic modeling.
RESULTS
The infusion of GLP-1 at a constant rate of 1.2 pmol/kg/ min
resulted in pharmacologically relevant plasma concentrations of
the intact hormone (Toft-Nielsen et al., 1999) (all plasma hor-
mones andmetabolites are depicted in Figure 1). During PET, the
PG concentrations remained at 3.06 ± 0.08 (GLP-1) and 3.09 ±
0.07 (placebo) mM, P = 0.55 for the treatment effect with simi-
lar glucose infusion rates (6.27 ± 2.7 vs. 5.58 ± 2.15mg/kg/min
GLP1 vs. placebo, P = 0.14). The plasma C-peptide level was
suppressed with no difference between sessions, P = 0.95. As
expected there were no significant differences in circulating hor-
mones and metabolites between sessions. Counter-regulatory
hormones rose as expected when PG declined. Insulin levels
were similar between sessions, P = 0.52 for the treatment effect,
as were GH levels, P = 0.12. Ghrelin (data not shown), nore-
pinephrine (data not shown), and epinephrine levels were also
similar during the sessions, P > 0.57. Serum cortisol concentra-
tions were significantly higher with GLP-1 at PG steps of 4.5
and 4.0mM, P = 0.0001 but were similar at PG steps of 3.5
FIGURE 1 | Total, intact GLP-1 concentrations, plasma glucose, insulin,
glucose infusion rate (GIR), C-peptide, glucagon, growth hormone,
epinephrine and cortisol during GLP-1 (black dot) and placebo (white
dot) infusion in different glucose clamp steps. GLP-1 infusion was
initiated at t = 60min. PET was performed from 300 to 360min. Data are
mean ± SEM. ∗P < 0.05.
and 3.0mM, P = 0.16 GLP-1 vs. placebo. The glucagon lev-
els increased with placebo infusion at PG step 4mM and the
glucagon levels were increased at PG step 3mM (significantly so at
270 and 330 min, P = 0.001 and 0.03, but not 300 and 360min,
P = 0.14 and 0.05) with GLP-1 infusion. PlasmaGLP-1 (total and
intact) levels differed between PET sessions, P < 0.001.
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FIGURE 2 | Unidirectional clearance (A), efflux rate constant for FDG
(B), phosphorylation coefficient for FDG (C), net clearance of
glucose (D), lumped constant (E), unidirectional glucose transfer (F),
cerebral metabolic rate for glucose (G), brain tissue glucose
concentration (H), and vascular volume (I) during placebo and
GLP-1 infusion. The regions are total cerebral gray matter (GM),
cerebral cortex (Cortex), thalamus (TH), striatum (ST), cerebellar cortex
(cerebellum), brain stem (BS) and white matter (WM). Black bars and
white bars represent placebo and GLP-1 respectively. Data are mean ±
SEM. ∗P < 0.05. P -value for overall GLP-1 effect on K1glc = 0.17;
P -value for overall GLP-1 effect on k∗2 = 0.57; P -value for overall GLP-1
effect on k∗3 = 0.48; P -value for overall GLP-1 effect on Kglc = 0.88;
P -value for overall GLP-1 effect on LC = 0.05; P -value for overall GLP-1
effect on Jglc = 0.23; P -value for overall GLP-1 effect on CMRglc = 0.96;
P -value for overall GLP-1 effect on Ctissue = 0.58; P -value for overall
GLP-1 effect on Vp = 0.003.
The magnitudes of the unidirectional clearance of glu-
cose (K1glc) were similar for GLP-1 vs. placebo in all regions
(P = 0.17, Figure 2A). The efflux rate constant for FDG (k∗2,
Figure 2B) did not change significantly (P = 0.57) with GLP-1
infusion, compared to placebo. No significant change occurred
for the phosphorylation rate constant for FDG (k∗3), P = 0.48
(Figure 2C), the net clearances of FDG (K∗, data not shown),
P = 0.62 or the net clearances of glucose (K), P = 0.88 with
GLP-1 infusion (Figure 2D). We found a tendency toward
decreased lumped constant with GLP-1 infusion in all regions,
P = 0.05 (P = 0.75 for interaction between region and treat-
ment) (Figure 2E). The volume of exchange (K1/k2 = K∗1 /k∗2) did
not change significantly with GLP-1 (P = 0.80, data not shown).
Unidirectional glucose flux (Jglc) was not significantly affected by
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GLP-1 infusion in any brain region (P = 0.87 for the interaction
between region and treatment and, subsequently, P = 0.23 for the
treatment effect) as shown in Figure 2F. Cerebral metabolic rate
for glucose (CMRglc) remained virtually unchanged in all regions
with GLP-1 infusion, P = 0.96, as did the cerebral tissue glucose
concentration (Ctissue) P = 0.58, (Figures 2G,H). The vascular
volume in the brain (Vp) decreased by 0.03ml/cm3 (95%CI 0.01–
0.05) with GLP-1 infusion, P = 0.003 with the same effect in all
regions (P = 0.63) (Figure 2I).
When we combined the data with our findings in hyper-
glycemia (Gejl et al., 2012a), we found that the maximum
phosphorylation velocity Vmax increased significantly in several
regions with GLP-1 (Figures 3A,B), including GM as a whole
(P = 0.03), cortex (P = 0.02), thalamus (P = 0.005), and cere-
bellum (P = 0.02). The difference between theMichaelis-Menten
curves of hexokinase activity was not explained by significantly
different affinity constants (KM) for the placebo and GLP-1 treat-
ments in any region (P-values above 0.22; data not shown).
The analysis of the maximum blood-brain glucose transport
capacity Tmax with GLP-1 (Figures 3C,D) revealed that Tmax
increased significantly in GM as a whole (P = 0.025), cortex
(P = 0.020), thalamus (P = 0.004), cerebellum (P = 0.040) and
white matter regions (P = 0.049), and the difference between the
Michaelis-Menten curves was not consistent with significantly
different affinity constants of the glucose transporter (Kt) in the
two sessions (P values above 0.17; data not shown).
DISCUSSION
In the present study, we found that effects of native GLP-1 in
the brain are dependent on PG concentration as in other tis-
sues, notably pancreatic beta cells (Degn et al., 2004). GLP-1
did not alter brain glucose metabolism or transport during
hypoglycemia, contrary to the effect in hyperglycemia (Gejl
et al., 2012a). GLP-1 lowered the vascular volume Vp in brain,
and, when pooled with data from the hyperglycemia study, we
demonstrated increased maximum phosphorylation velocity and
increased transport capacity with GLP-1 in specific gray andwhite
matter regions.
Normal brain function depends on a continuous supply of glu-
cose by the cerebral circulation, and blood-brain glucose transfer
normally is affected chiefly by changes of the PG level (Gjedde,
1983). Thus, hypoglycemia lowers unidirectional blood-brain
FIGURE 3 | Michaelis-Menten curves reflecting phosphorylation velocity
responding Ctissue in thalamus with and without GLP-1 (A) and
Michaelis-Menten curves reflecting unidirectional glucose transport
responding PG in thalamus with and without GLP-1 (C) and bar charts
comparing maximum phosphorylation velocity Vmax (B) and maximum
transport capacity Tmax (D) in the seven regions. Data in (A) and (C) are
estimates and the bar chart (B) and (D) are estimates ± SE. ∗P ≤ 0.05.
P -value for Vmax in GM = 0.03, cortex = 0.02, thalamus = 0.005, and
cerebellum = 0.02. P -value for Tmax in GM = 0.025, WM = 0.049, cortex =
0.020, thalamus = 0.004, and cerebellum = 0.040.
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glucose transfer as described by the Michaelis-Menten equation.
In healthy humans, blood glucose below 3mM acutely induces
brain dysfunction and hypoglycemic symptoms (Maran et al.,
1995). Hence the main defense of patients with insulin-treated
diabetes is subjective recognition of symptoms such as sweat-
ing, hunger, and tremor. An estimated 2–4% of deaths of people
with type 1 diabetes have been attributed to hypoglycemia (Cryer,
2004), and hypoglycemia also occurs in type 2 diabetes with
prevalence rates of 70–80% in clinical trials of insulin (UKPDS,
1998; Jensen et al., 2010). However, a significant number of these
patients are unaware of the hypoglycemia with no warning prior
to cognitive dysfunction with severe symptoms such as confusion
and coma (Bingham et al., 2005). One report indicates that a rela-
tive rise of CMRglc occurs in aware subjects during hypoglycemia
in contrast to a relative fall in unaware subjects (Bingham et al.,
2005). Changes in cerebral glucose uptake have been associated
with recurrent hypoglycemic events and are believed to be a risk
factor for hypoglycemic unawareness (Boyle et al., 1994; Bingham
et al., 2005).
It is uncertain how GLP-1 lowers the Ctissue during hyper-
glycemia, but we reason that the most likely effect would be on
the CMRglc by change of the maximum phosphorylation velocity,
e.g., by influencing the activity of hexokinase to a greater extent
than the transporter density in the endothelial membranes. If so,
GLP-1 could further lower tissue glucose in hypoglycemia.
The current study tested the expectation that the effects
of GLP-1 on brain glucose content, blood-brain glucose
metabolism, and blood-brain glucose transfer, are additive in
hypoglycemia because of the possibly enhanced CMRglc and Jglc
noted in hyperglycemia, but the results were not consistent with
this prediction. In hypoglycemia, we noted a numerical but sta-
tistically insignificant increase of the blood-brain glucose transfer
in the presence of GLP-1. The cerebral metabolic rate and the
cerebral tissue glucose concentration also remained constant. The
results are consistent with the interpretation that the effects of
GLP-1 are glucose-dependent, as they are in pancreas. The GLP-1
secretion is preserved during hypoglycemia (Poulsen et al., 2000)
and GLP-1 enhances glucose-induced insulin secretion from the
pancreatic β-cells via the G-protein coupled GLP-1R leading
to an intracellular cAMP increase. Furthermore, GLP-1 inhibits
glucagon secretion from the pancreatic α-cells at fasting and
elevated glucose concentrations, whereas hypoglycemia induced
glucagon secretion is not inhibited—the mechanisms involved
are not fully understood (Nauck et al., 2002). Slightly higher
glucagon levels during hypoglycemia in the GLP-1 group com-
pared to the control experiments was previously found in studies
with the GLP-1 analog exenatide (Degn et al., 2004) and the DPP-
IV inhibitor Vildagliptin (Ahren et al., 2009). Glucagon levels
do not seem to affect BBB glucose transport or cerebral glucose
metabolism (Segel et al., 2001). Judging from the results of both
studies, the effect of GLP-1 on blood-brain glucose metabolism
and transfer is the result of a combination of increased maxi-
mum phosphorylation velocity and unchanged hexokinase affin-
ity, coupled with a significant increase of the transport capacity in
most regions and unaltered glucose transporter affinity.
Kinetically, the rates of unidirectional glucose transfer are not
rate-limiting for glucose metabolism under normal conditions.
However, when PG declines below a certain threshold, the deliv-
ery and transport of glucose from blood to brain ultimately
fail to support the rate of glucose utilization, with the conse-
quence of impaired brain energy turnover (Pardridge, 1983).
The transport capacity is not closely coupled to the metabolic
rate but rather influences the balance between glucose delivery
and metabolism as reflected in the Ctissue. Changes of Vmax or
Tmax with unchanged KM or Kt or both are therefore impor-
tant determinants of Ctissue when the metabolic rate and plasma
and tissue glucose increase. Because of the very high affinity of
hexokinase to glucose, the increase of Vmax is consistent with an
increased metabolism of glucose in response to GLP-1 infusion,
depending on the prevailing plasma levels of glucose. The mech-
anism is speculative; but as the maximum activity of hexokinase
appears to be increased, by a GLP-1 mediated activation of the
AMP-activated protein kinase (AMPK) is suggested by evidence
from an animal stroke model (Hou et al., 2012), with possible
increase of metabolism and GLUT1 activity (Ronnett et al., 2009;
Cura and Carruthers, 2012). Tmax increased in various regions.
Another possible link, published by Mathiisen et al. has shown
that astrocytes participate in some functions of the BBB by cover-
ing the capillaries (Mathiisen et al., 2010), and therefore astrocytic
activity may contribute to the changes observed in response to
GLP-1.
Several studies suggest that blood–brain transfer of glucose
may be down-regulated in poorly controlled diabetes (Gjedde
and Crone, 1981; McCall, 2004). There is some evidence that
patients with diabetes with increased PG concentrations may
develop cerebral symptoms of hypoglycemia when PG rapidly
is lowered to normal concentrations, possibly due to repres-
sive changes of the glucose transport mechanism occurring in
the endothelial cells in response to hyperglycemia (Gjedde and
Crone, 1981), although the findings are equivocal (Wang et al.,
2012). Here, we report opposite results of GLP-1, consistent with
increased transport capacity. The elevated transport is of consid-
erable potential interest to the treatment of patients with insulin
in whom the co-treatment with GLP-1 might prevent adverse
effects from glucopenia.
At the glucose concentrations in blood and brain that prevail
in the present study and the previous study, transport is never
saturated, whereas phosphorylation by hexokinase is moderately
unsaturated in hypoglycemia. In hyperglycemia, phosphorylation
is at maximum, although net transport may still change and
transfer more glucose across the BBB, raising intracellular glu-
cose without affecting the flux through hexokinase and hence the
glycolytic rate.
Blood-brain glucose transfer rarely limits glucose metabolism,
but glucose transport across the BBB in principle can be stimu-
lated by (1) increasing the glucose gradient and thereby raising
the difference between the glucose fluxes in the two directions
across the BBB, (2) increasing intrinsic activity of GLUT-1, or its
affinity, or (3) increasing the functionally available GLUT-1 car-
riers in the BBB by inserting new GLUT proteins with or without
increasing the capillary surface area available for facilitated glu-
cose entry (Leybaert, 2005). Together, the latter two mechanisms
define the maximum transport capacity (Tmax). The results sug-
gest intrinsic changes of the GLUT-1 carrier, or increasing density
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of GLUT-1 in the BBB, based on similar affinity constants (Kt)
and decreased plasma volumes in brain (Vp) in hypoglycemia and
unaltered Vp in the hyperglycemia. Thus we postulate a direct
effect of GLP-1 on the GLUT1 properties in the membranes of
the BBB, with a possible link by means of AMPK activation.
Cerebral blood flowwas notmeasured in the current study, but
the net and unidirectional blood-brain clearances (K and K1) in
principle are measures that incorporate blood flow effects, being
equal to the product of the extraction fraction (net or unidi-
rectional) and the plasma flow. The clearance in turn yields the
substrate flux when multiplied with the substrate concentration.
The trend toward decline of the lumped constant with GLP-1
in hypoglycemia is a further indication of the potentially protec-
tive effect of the peptide, because the rise of the lumped constant
in hypoglycemia is the obligatory result of the effect of low glu-
cose on the competition between the tracer FDG and native
glucose (Gjedde et al., 1985). Hence, a lower lumped constant is
an indicator of possibly less perturbed glucose concentration.
We observed a decrease of Vp with GLP-1 infusion. The vascu-
lar volume is the part of tissue volume occupied by intravascular
blood. Although the degree of hypoglycemia was low in the
present study, Vp was still higher than in hyperglycemia, particu-
larly in the placebo group. A similar increase was reported earlier
(Kennan et al., 2005). GLP-1 is a peripheral vasodilator in several
parts of the body (Grieve et al., 2009; Gejl et al., 2012b), sug-
gesting that the Vp decline could be a sympathetic autoregulatory
reaction of the cerebral vasculature to lowered arterial blood pres-
sure. In this context, it is worthwhile to consider the physiology of
glucose transport: At a PG of 3.0mM, the extraction fraction of
glucose is not threateningly high (Crone, 1965), but it is close to
the threshold where perfusion changes may become important,
particularly when PG decreases further. The Vp decrease has no
impact on other observations, as Vp refers to the vascular volume
and not to the cerebral blood flow. Because of the autoregulatory
nature of cerebral blood flow, glucose kinetics remain unaffected.
It is highly debated whether GLP-1 crosses the BBB, or the
central effects of GLP-1 and analogues are mediated by leaks
through the BBB of the circumventricular organs, and the ques-
tion remains an area of investigation (Holst et al., 2011), although
our results indicate an impact in the brain due to increased
metabolism of glucose when glucose is present at normal or
higher than normal concentrations.
The dependence of the present analysis on data reported pre-
viously raises the issue of comparability of the two experiments,
but the analysis of Michaelis-Menten constants requires a wide
spectrum of transport and metabolism fluxes vs. glucose concen-
trations, as obtained in the two studies with the same designs
designs in terms of clamp and PET procedure. The participants
could not participate in both studies because of the exposure
to ionizing radiation, but the demographics were the same. The
Michaelis-Menten estimates are based on region-of-interest anal-
ysis within the group (hypo- or hyperglycemic) and were not
individually calculated.
We conclude that the GLP-1-induced effect on BBB glucose
transfer and metabolism in brain, and hence brain glucose con-
tent, are glucose-concentration dependent, rendering changes
insignificant in hypoglycemia. GLP-1 increases the maximum
phosphorylation velocity of glucose without a significant change
in affinity of glucose to hexokinase. We found that GLP-1 did
affect Tmax in gray matter regions of cortex, thalamus, cerebel-
lum, and white matter regions with unaltered affinity of GLUT1
to glucose. The observation that the effects of GLP-1 on glucose
transport and metabolism vanish at low glucose concentrations
contributes to a more complete understanding of GLP-1’s gener-
ally beneficial actions in brain. Thus, under conditions of phar-
macologically elevated levels of GLP-1, we note that GLP-1 has
no deleterious effect on brain glucose transport in hypoglycemia
where glucose availability is low, and thus does not exacerbate the
effects of hypoglycemia per se.
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